

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

*Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the
Drug Safety and Risk Management (DSaRM) Advisory Committee*

October 8, 2020

DRAFT MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

LaToya Bonner, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Walter S. Dunn, MD, PhD

Assistant Clinical Professor
University of California Los Angeles (UCLA)
Department of Psychiatry
Director, Mood Disorders Clinic
West Los Angeles Veterans Administration
Medical Center
Los Angeles, California

Jess G. Fiedorowicz, MD, PhD

Head and Chief, Department of Mental Health
The Ottawa Hospital
Professor and Senior Research Chair in Adult
Psychiatry, Department of Psychiatry
University of Ottawa
Ottawa, Ontario

Satish Ivengar, PhD

Chair and Professor of Statistics
Department of Statistics
University of Pittsburgh
Pittsburgh, Pennsylvania

Felipe A. Jain, MD

Assistant Professor of Psychiatry
Harvard Medical School
Director of Healthy Aging Studies
Depression Clinical and Research Program
Massachusetts General Hospital
Boston, Massachusetts

Jessica J. Jeffrey, MD, MPH, MBA

Assistant Clinical Professor of Psychiatry
Associate Director, Division of Population
Behavioral Health
Nathanson Family Resilience Center
UCLA Semel Institute of Neuroscience and
Human Behavior
Los Angeles, California

Sonia L. Krishna, MD, FAPA, DFAACAP

Affiliate Faculty, Department of Psychiatry
Dell Medical School
The University of Texas at Austin
Austin, Texas

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

***Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the
Drug Safety and Risk Management (DSaRM) Advisory Committee***

October 8, 2020

DRAFT MEETING ROSTER (cont.)

**PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)
(cont.)**

Rajesh Narendran, MD

(Chairperson)

Attending Psychiatrist

Re:solve Crisis Network

Western Psychiatric Institute and Clinics

Associate Professor in Radiology and Psychiatry

Psychiatric Molecular Imaging Program

University of Pittsburgh

Pittsburgh, Pennsylvania

Patrick S. Thomas, Jr., MD, PhD

Assistant Professor, Department of Psychiatry

Baylor College of Medicine, Menninger Clinic

Houston, Texas

Kim O. Witzak

(Consumer Representative)

Co-Founder, Executive Director

Woodymatters

Minneapolis, Minnesota

PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Robert W. Baker, MD

(Industry Representative)

Vice President, Clinical Program Design

Eli Lilly and Company

Lilly Corporate Center

Indianapolis, Indiana

**DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEMBERS
(Voting)**

Denise M. Boudreau, PhD, RPh

Senior Scientific Investigator

Kaiser Permanente Health Research Institute

Kaiser Permanente Washington

Professor (Affiliate)

Departments of Pharmacy and Epidemiology

University of Washington

Seattle, Washington

Karim Anton Calis, PharmD, MPH,

FASHP, FCCP

Director of Clinical Research and Compliance

Office of the Scientific Director

Eunice Kennedy Shriver National Institute of

Child Health and Human Development

National Institutes of Health

Bethesda, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

*Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the
Drug Safety and Risk Management (DSaRM) Advisory Committee*
October 8, 2020

DRAFT MEETING ROSTER (cont.)

**DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEMBERS
(Voting) (cont.)**

Marie R. Griffin, MD, MPH

Professor of Health Policy, Emerita
Department of Health Policy
Vanderbilt University
Nashville, Tennessee

Laurel A. Habel, MPH, PhD

Associate Director, Cancer Research
Division of Research
Kaiser Permanente Northern California
Oakland, California

Sonia Hernandez-Diaz, MD, MPH, DrPH

(Chairperson)
Professor of Epidemiology
Department of Epidemiology
Harvard T.H. Chan School of Public Health
Boston, Massachusetts

Martin Kulldorff, PhD

Professor of Medicine and Biostatistician
Division of Pharmacoepidemiology and
Pharmacoeconomics
Department of Medicine
Harvard Medical School and Brigham & Women's
Hospital
Boston, Massachusetts

Steven B. Meisel, PharmD, CPPS

System Director of Medication Safety
M Health Fairview
Minneapolis, Minnesota

Lewis S. Nelson, MD

Professor and Chair
Department of Emergency Medicine
Chief, Division of Medical Toxicology
Rutgers New Jersey Medical School
Newark, New Jersey

**DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEMBER
(Non-Voting)**

Reema J. Mehta, PharmD, MPH

(Industry Representative)
Senior Director, Head of Risk Management and
Safety Surveillance Research
Pfizer, Inc.
North Peapack, New Jersey

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

*Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the
Drug Safety and Risk Management (DSaRM) Advisory Committee*
October 8, 2020

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Traci C. Green, PhD, MSc

Professor
Heller School for Social Policy and Management
Director
Opioid Policy Research Collaborative
Brandeis University
Waltham, Massachusetts

Brandon D.L. Marshall, PhD

Associate Professor
Department of Epidemiology
Brown University School of Public Health
Providence, Rhode Island

**Christopher R. McCurdy, BScPh, PhD,
FAAPS**

Director
UF Clinical and Translational Science Institute
Translational Drug Development Core
Professor of Medicinal Chemistry
Department of Medicinal Chemistry
University of Florida, College of Pharmacy
Gainesville, Florida

James J. McGough, MD, MS

Professor of Clinical Psychiatry
UCLA Semel Institute for Neuroscience &
Human Behavior
Los Angeles, California

Philip Posner, PhD

(Patient Representative)
Gainesville, Florida

Jon E. Zibbell, PhD

Senior Public Health Scientist
Behavioral Health Research Division
RTI International
Century Plaza 1
Atlanta, Georgia

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

*Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the
Drug Safety and Risk Management (DSaRM) Advisory Committee*

October 8, 2020

DRAFT MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Billy Dunn, MD

Director (Acting)
Office of Neuroscience (ON)
Office of New Drugs (OND), CDER, FDA

Eric Bastings, MD

Deputy Director (Acting)
ON, OND, CDER, FDA

Tiffany R. Farchione, MD

Director (Acting)
Division of Psychiatry (DP)
ON, OND, CDER, FDA

Bernard Fischer, MD

Deputy Director (Acting)
DP, ON, OND, CDER, FDA

Judy Staffa, PhD, RPh

Associate Director for the Public Health
Initiatives
Office of Surveillance and Epidemiology (OSE)
CDER, FDA

Tamra Meyer, PhD, MPH

Team Lead, Nonmedical Use Team #1
Division of Epidemiology II (DEPI-II)
Office of Pharmacovigilance and
Epidemiology (OPE)
OSE, CDER, FDA

Dominic Chiapperino, PhD

Director
Controlled Substance Staff (CSS)
Office of the Center Director (OCD)
CDER, FDA